Tiziana Reports Positive Phase 2a INFORM-MS Trial Results

Tiziana said its Phase 2a INFORM-MS trial of intranasal foralumab met both primary endpoints. The supplied body says one endpoint showed a statistically significant reduction (p=0.0168), but ends before identifying what was reduced.